JP2020196672A - Vitamin B12-containing composition - Google Patents
Vitamin B12-containing composition Download PDFInfo
- Publication number
- JP2020196672A JP2020196672A JP2019102033A JP2019102033A JP2020196672A JP 2020196672 A JP2020196672 A JP 2020196672A JP 2019102033 A JP2019102033 A JP 2019102033A JP 2019102033 A JP2019102033 A JP 2019102033A JP 2020196672 A JP2020196672 A JP 2020196672A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- weight
- composition
- fatty acid
- sorbitan fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 229930003779 Vitamin B12 Natural products 0.000 title abstract 7
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 title abstract 7
- 239000011715 vitamin B12 Substances 0.000 title abstract 7
- 235000019163 vitamin B12 Nutrition 0.000 title abstract 7
- -1 fatty acid ester Chemical class 0.000 claims abstract description 52
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 27
- 239000000194 fatty acid Substances 0.000 claims abstract description 27
- 229930195729 fatty acid Natural products 0.000 claims abstract description 27
- 229920001214 Polysorbate 60 Polymers 0.000 claims abstract description 22
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical class [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 49
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 36
- 229930003427 Vitamin E Natural products 0.000 claims description 15
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 15
- 239000011709 vitamin E Substances 0.000 claims description 15
- 235000019165 vitamin E Nutrition 0.000 claims description 15
- 229940046009 vitamin E Drugs 0.000 claims description 15
- 229940125904 compound 1 Drugs 0.000 claims description 5
- 238000000354 decomposition reaction Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 29
- 239000000047 product Substances 0.000 description 18
- 235000000639 cyanocobalamin Nutrition 0.000 description 17
- 239000011666 cyanocobalamin Substances 0.000 description 17
- 229960002104 cyanocobalamin Drugs 0.000 description 17
- 229930003270 Vitamin B Natural products 0.000 description 16
- 235000019156 vitamin B Nutrition 0.000 description 16
- 239000011720 vitamin B Substances 0.000 description 16
- FEZWOUWWJOYMLT-DSRCUDDDSA-M cobalt;[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,1 Chemical compound [Co].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FEZWOUWWJOYMLT-DSRCUDDDSA-M 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 8
- 239000002738 chelating agent Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 229930003799 tocopherol Natural products 0.000 description 7
- 239000011732 tocopherol Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 6
- 229940068968 polysorbate 80 Drugs 0.000 description 6
- 150000005846 sugar alcohols Polymers 0.000 description 6
- 235000010384 tocopherol Nutrition 0.000 description 6
- 229960001295 tocopherol Drugs 0.000 description 6
- 125000002235 cyanocobalamin group Chemical group 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000551 dentifrice Substances 0.000 description 4
- 238000005562 fading Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001219 Polysorbate 40 Polymers 0.000 description 2
- 229920002651 Polysorbate 85 Polymers 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 229940049918 linoleate Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940113171 polysorbate 85 Drugs 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 229930003802 tocotrienol Natural products 0.000 description 2
- 239000011731 tocotrienol Substances 0.000 description 2
- 235000019148 tocotrienols Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- DEKFZWMENCCOFU-LIKAHPKFSA-N 2-[(2r)-2-[(2r,3s,4r)-3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC[C@@H](OCCO)[C@H]1OC[C@@H](OCCO)[C@@H]1OCCO DEKFZWMENCCOFU-LIKAHPKFSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 206010013029 Diphyllobothriasis Diseases 0.000 description 1
- 241001137876 Diphyllobothrium Species 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- WBSXYJYELWQLCJ-UHFFFAOYSA-K cobalt(3+);[5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1h-corrin-21-id-3-yl]propanoylamino]propan-2 Chemical compound O.[OH-].[Co+3].OCC1OC(N2C3=CC(C)=C(C)C=C3N=C2)C(O)C1OP([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O WBSXYJYELWQLCJ-UHFFFAOYSA-K 0.000 description 1
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 1
- 235000006279 cobamamide Nutrition 0.000 description 1
- 239000011789 cobamamide Substances 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000036654 deficiency anemia Diseases 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940102545 peg-20 sorbitan isostearate Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
本発明は、ビタミンＢ12類を含み、光暴露によるビタミンＢ12類の分解が抑制されている組成物に関する。 The present invention includes a vitamin B 12 compounds, to compositions which decomposition of vitamin B 12 compound by light exposure is inhibited.
ビタミンＢ12類は、水溶性ビタミンの一種であり、生命を維持するために不可欠な栄養素である。ビタミンＢ12類は、ビタミンＢ12類欠乏症、巨赤芽球性貧血、広節裂頭条虫症、悪性貧血、吸収不全症候群、眼精疲労、栄養性貧血、妊娠性貧血、神経痛等の症状の予防又は改善、肌荒れ改善等に有効であることが知られており、飲食品、口腔ケア製品、医薬品、化粧料等で使用されている。一方、ビタミンＢ12類は、光暴露により分解され易いことが知られており、ビタミンＢ12類を含む製品を実用化する上では、ビタミンＢ12類に対して光安定性を備えさせることが不可欠になっている。 Vitamin B 12 is a kind of water-soluble vitamin and is an essential nutrient for sustaining life. Vitamin B 12 is a symptom of vitamin B 12 deficiency, megaloblastic anemia, fish tapeworm, pernicious anemia, malabsorption syndrome, eye fatigue, nutritional anemia, gestational anemia, nerve pain, etc. It is known to be effective for prevention or improvement of skin irritation, improvement of rough skin, etc., and is used in foods and drinks, oral care products, pharmaceuticals, cosmetics, etc. On the other hand, vitamin B 12 compound, it tends to be decomposed by light exposure are known, the practical use of products containing vitamin B 12 compound may be caused to comprise a light stable against vitamin B 12 compound It has become indispensable.
従来、ビタミンＢ12類に光安定性を備えさせる製剤技術について種々報告されている。例えば、特許文献１には、ビタミンＢ12、及びブタノールを含む製剤が、ビタミンＢ12に光安定性を付与できることが開示されている。また、特許文献２には、ビタミンＢ12、及び特定のフェニルプロペンカルボニル構造を有するビタミン安定剤を含むビタミン組成物が、ビタミンＢ12に光安定性を付与できることが開示されている。また、特許文献３には、ビタミンＢ12にシクロデキストリン又はその誘導体を添加することによって、ビタミンＢ12に光安定化が図られることが開示されている。 Conventionally, various preparation techniques for making vitamin B 12s have photostability have been reported. For example, Patent Document 1 discloses that a preparation containing vitamin B 12 and butanol can impart photostability to vitamin B 12 . Further, Patent Document 2, vitamin compositions comprising vitamin stabilizer comprising a vitamin B 12, and the particular phenylpropenoic carbonyl structure, it is disclosed that can be imparted to light stability to vitamin B 12. Further, Patent Document 3, by the addition of cyclodextrin or a derivative thereof to vitamin B 12, it is disclosed that the light stabilizing vitamin B 12 is achieved.
このように、従来、ビタミンＢ12類の光安定化を図る製剤技術については検討されているものの、近年、製品の多様化や品質向上に対する要望が向上しており、このような要望に追従するために、ビタミンＢ12類の光安定化を図る新たな技術の開発が望まれている。 As described above, although the formulation technology for photostabilizing vitamin B 12s has been studied in the past, the demand for product diversification and quality improvement has been increasing in recent years, and it follows such demand. Therefore, it is desired to develop a new technology for photostabilizing vitamin B 12s .
本発明の目的は、ビタミンＢ12類を含み、光暴露によるビタミンＢ12類の分解が抑制されている組成物を提供することである。 An object of the present invention includes a vitamin B 12 compound is to provide a composition which decomposition of vitamin B 12 compound by light exposure is inhibited.
本発明者は、前記課題を解決すべく鋭意検討を行ったところ、ビタミンＢ12類を含む組成物にポリオキシエチレンソルビタン脂肪酸エステルを含有させ、且つビタミンＢ12類１重量部に対してポリオキシエチレンソルビタン脂肪酸エステルが１０重量部以下となるように設定することにより、過酷な条件で光暴露を行ってもビタミンＢ12類の分解を抑制でき、ビタミンＢ12類に対する光安定化効果が格段顕著に奏されることを見出した。本発明は、かかる知見に基づいて、更に検討を重ねることにより完成したものである。 The present inventors have was subjected to solve intensive study of the problem, a composition comprising a vitamin B 12 compound is a polyoxyethylene sorbitan fatty acid esters, and polyoxy against vitamin B 12 compound 1 part by weight by sorbitan fatty acid ester is set to be equal to or less than 10 parts by weight, even when the light exposure under severe conditions can inhibit the decomposition of vitamin B 12 compound, remarkably conspicuous light stabilizing effect on vitamin B 12 compound I found that it was played by. The present invention has been completed by further studies based on such findings.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項１． ビタミンＢ12類及びポリオキシエチレンソルビタン脂肪酸エステルを含有し、且つビタミンＢ12類１重量部当たりポリオキシエチレンソルビタン脂肪酸エステルが１０重量部以下である、ビタミンＢ12類含有組成物。
項２． 更にビタミンＥ類を含有する、項１に記載のビタミンＢ12類含有組成物。
項３． ビタミンＢ12類１重量部当たりビタミンＥ類が０．００１２５〜１０００重量部である、項２に記載のビタミンＢ12類含有組成物。
項４． 水性組成物である、項１〜３のいずれかに記載のビタミンＢ12類含有組成物。
That is, the present invention provides the inventions of the following aspects.
Item 1. Containing vitamin B 12 acids and polyoxyethylene sorbitan fatty acid esters, and vitamin B 12 compound 1 part by weight per polyoxyethylene sorbitan fatty acid ester is less than 10 parts by weight, vitamin B 12 analog-containing composition.
Item 2. Item 2. The composition containing vitamin B 12s , which further contains vitamin Es.
Item 3. Item 2. The composition containing vitamin B 12 according to Item 2, wherein the amount of vitamin E per part by weight of vitamin B 12 is 0.00125 to 1000 parts by weight.
Item 4. Item 2. The composition containing vitamin B 12 according to any one of Items 1 to 3, which is an aqueous composition.
本発明によれば、光暴露によるビタミンＢ12類の分解を抑制できるので、ビタミンＢ12類を含む各種製品の保存安定性を向上させることが可能になる。 According to the present invention, since the decomposition of vitamin B 12s due to light exposure can be suppressed, it is possible to improve the storage stability of various products containing vitamin B 12s .
１．ビタミンＢ 12 類含有組成物
本発明のビタミンＢ12類含有組成物は、ビタミンＢ12類及びポリオキシエチレンソルビタン脂肪酸エステルを含有し、且つビタミンＢ12類１重量部当たりポリオキシエチレンソルビタン脂肪酸エステルが１０重量部以下であることを特徴とする。以下、本発明のビタミンＢ12類含有組成物について、詳述する。
1. 1. Vitamin B 12 compounds containing composition of vitamin B 12 analog-containing composition the present invention contains a vitamin B 12 acids and polyoxyethylene sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid ester per and vitamin B 12 compound 1 part by weight It is characterized in that it is 10 parts by weight or less. Hereinafter, the vitamin B 12- containing composition of the present invention will be described in detail.
［ビタミンＢ12類］
ビタミンＢ12類とは、ビタミンＢ12（シアノコバラミン）、その誘導体、及びそれらの塩を指す。本発明で使用されるビタミンＢ12類の種類については、飲食品、口腔ケア製品、医薬品、化粧料等の製品に配合可能であることを限度として特に制限されない。例えば、ビタミンＢ12の誘導体としては、メチルコバラミン、ヒドロキソコバラミン、アデノシルコバラミン、アクアコバラミン等が挙げられる。また、ビタミンＢ12及びその誘導体の塩としては、例えば、酢酸塩、トリフルオロ酢酸塩、酪酸塩、パルミチン酸塩、ステアリン酸塩、フマル酸塩、マレイン酸塩、コハク酸塩、マロン酸塩、乳酸塩、酒石酸塩、クエン酸塩等のカルボン酸塩；メタンスルホン酸塩、トルエンスルホン酸塩、トシル酸塩等の有機スルホン酸塩；塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩；メチルアミン、トリエチルアミン、トリエタノールアミン等の有機アミン塩；ナトリウム塩、カリウム塩等のアルカリ金属塩；カルシウム、マグネシウム等のアルカリ土類金属塩；アンモニウム塩等が挙げられる。
[Vitamin B 12 ]
Vitamin B 12s refer to vitamin B 12 (cyanocobalamin), its derivatives, and salts thereof. For the types of vitamin B 12 compound for use in the present invention is not particularly limited as limit the food products, oral care products, pharmaceuticals, can be formulated into products of cosmetics. For example, derivatives of vitamin B 12 include methylcobalamin, hydroxocobalamin, adenosylcobalamin, aquacobalamin and the like. Examples of salts of Vitamin B 12 and its derivatives include acetate, trifluoroacetate, butyrate, palmitate, stearate, fumarate, maleate, succinate, malonate, and the like. Carbolates such as lactates, tartrates and citrates; organic sulfonates such as methanesulfonates, toluenesulfonates and tosylates; inorganic acids such as hydrochlorides, sulfates, nitrates and phosphates Salts; organic amine salts such as methylamine, triethylamine, triethanolamine; alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium and magnesium; ammonium salts and the like.
これらのビタミンＢ12類は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These vitamin B 12s may be used alone or in combination of two or more.
これらのビタミンＢ12類の中でも、好ましくはシアノコバラミンが挙げられる。 Among these vitamin B 12 compounds, preferably include cyanocobalamin.
本発明のビタミンＢ12類含有組成物におけるビタミンＢ12類の濃度については、当該ビタミンＢ12類含有組成物の形状や製品形態等に応じて適宜設定すればよいが、例えば、０．０００１〜０．２重量％、好ましくは０．０００２〜０．０２重量％、より好ましくは０．０００２〜０．００２重量％が挙げられる。 The concentration of vitamin B 12 rocks in vitamin B 12 analog-containing composition of the present invention may be appropriately set according to the shape and product forms like of the vitamin B 12 analog-containing composition, but for example, 0.0001 0.2% by weight, preferably 0.0002 to 0.02% by weight, more preferably 0.0002 to 0.002% by weight.
［ポリオキシエチレンソルビタン脂肪酸エステル］
本発明のビタミンＢ12類含有組成物は、ビタミンＢ12類の光安定化を図るために、ビタミンＢ12類１重量部に対して１０重量部以下となる比率でポリオキシエチレンソルビタン脂肪酸エステルを含有する。
[Polyoxyethylene sorbitan fatty acid ester]
Vitamin B 12 compounds containing composition of the present invention, in order to light stabilization of vitamin B 12 compound, a polyoxyethylene sorbitan fatty acid esters in a ratio of 10 parts by weight or less with respect to vitamin B 12 compound 1 part by weight contains.
ポリオキシエチレンソルビタン脂肪酸エステルとは、脂肪酸とソルビタンとのモノエステル、ジエステル、又はトリエステルであるソルビタン脂肪酸エステルにエチレンオキサイドが縮合している化合物である。ポリオキシエチレンソルビタン脂肪酸エステルを構成する脂肪酸の炭素数としては、例えば、８〜３０、好ましくは１０〜２２、より好ましくは１２〜１８が挙げられる。また、ポリオキシエチレンソルビタン脂肪酸エステルに縮合されているエチレンオキサイドの平均付加モル数としては、例えば、６〜１６０、好ましくは６〜６０、より好ましくは６〜３０が挙げられる。ポリオキシエチレンソルビタン脂肪酸エステルとしては、具体的には、ポリソルベート２０（ポリオキシエチレン（２０）ソルビタンモノパルミテート）、ポリソルベート４０（ポリオキシエチレン（２０）ソルビタンモノラウレート）、ポリソルベート６０（ポリオキシエチレン（２０）ソルビタンモノステアレート）、ポリソルベート６５（ポリオキシエチレン（２０）ソルビタントリステアレート）、ポリソルベート８０（ポリオキシエチレン（２０）ソルビタンモノオレエート）、ポリソルベート８５（ポリオキシエチレン（２０）ソルビタントリオレエート）、ステアリン酸ＰＥＧ−６ソルビタン、イソステアリン酸ＰＥＧ−２０ソルビタン、オレイン酸ＰＥＧ−６ソルビタン、ポリソルベート８５等が挙げられる。 The polyoxyethylene sorbitan fatty acid ester is a compound in which ethylene oxide is condensed with a sorbitan fatty acid ester which is a monoester, a diester, or a triester of a fatty acid and sorbitan. Examples of the carbon number of the fatty acid constituting the polyoxyethylene sorbitan fatty acid ester include 8 to 30, preferably 10 to 22, and more preferably 12 to 18. The average number of moles of ethylene oxide condensed on the polyoxyethylene sorbitan fatty acid ester is, for example, 6 to 160, preferably 6 to 60, and more preferably 6 to 30. Specific examples of the polyoxyethylene sorbitan fatty acid ester include polysorbate 20 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 40 (polyoxyethylene (20) sorbitan monolaurate), and polysorbate 60 (polyoxyethylene). (20) sorbitan monostearate), polysorbate 65 (polyoxyethylene (20) sorbitan tristearate), polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), polysorbate 85 (polyoxyethylene (20) sorbitan trioleate). Ate), PEG-6 sorbitan stearate, PEG-20 sorbitan isostearate, PEG-6 sorbitan oleate, polysorbate 85 and the like.
これらのポリオキシエチレンソルビタン脂肪酸エステルは、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These polyoxyethylene sorbitan fatty acid esters may be used alone or in combination of two or more.
これらのポリオキシエチレンソルビタン脂肪酸エステルの中でも、より一層効果的にビタミンＢ12類の光安定化を図るという観点から、好ましくはポリソルベート８０が挙げられる。 Among these polyoxyethylene sorbitan fatty acid esters, from the viewpoint of more effectively achieving the photostability of the vitamin B 12 compounds, preferably polysorbates 80.
本発明のビタミンＢ12類含有組成物において、ビタミンＢ12類とポリオキシエチレンソルビタン脂肪酸エステルとを共存させる際の両者の比率としては、ビタミンＢ12類１００重量部当たり、ポリオキシエチレンソルビタン脂肪酸エステルが１０重量部以下であればよいが、好ましくは１〜１０重量部、より好ましくは２．５〜１０重量部が挙げられる。 In the composition containing vitamin B 12 of the present invention, the ratio of both vitamin B 12 and polyoxyethylene sorbitan fatty acid ester when coexisting with them is as follows: polyoxyethylene sorbitan fatty acid ester per 100 parts by weight of vitamin B 12 It may be 10 parts by weight or less, but preferably 1 to 10 parts by weight, more preferably 2.5 to 10 parts by weight.
また、本発明のビタミンＢ12類含有組成物におけるポリオキシエチレンソルビタン脂肪酸エステルの濃度については、前記比率を充足する範囲で適宜設定すればよいが、例えば、０．００１〜０．１重量％、好ましくは０．００２５〜０．１重量％、より好ましくは０．００５〜０．１重量％が挙げられる。 The concentration of the polyoxyethylene sorbitan fatty acid ester in the composition containing vitamin B 12 of the present invention may be appropriately set within a range that satisfies the above ratio, and is, for example, 0.001 to 0.1% by weight. It is preferably 0.0025 to 0.1% by weight, more preferably 0.005 to 0.1% by weight.
［ビタミンＥ類］
本発明のビタミンＢ12類含有組成物には、ビタミンＢ12類及びポリオキシエチレンソルビタン脂肪酸エステルに加えてビタミンＥ類を含有していてもよい。このようにビタミンＥ類を更に含有させることにより、より一層効果的にビタミンＢ12類の光安定化を図ることが可能になる。
[Vitamin E]
The vitamin B 12- containing composition of the present invention may contain vitamin E in addition to vitamin B 12 and polyoxyethylene sorbitan fatty acid ester. By thus further contain vitamin E, the more it can be more effectively reduced the photostability of the vitamin B 12 compound.
ビタミンＥ類とは、ビタミンＥ（トコフェロール、トコトリエノール）、及びその誘導体を指す。本発明で使用されるビタミンＥ類の種類については、飲食品、口腔ケア製品、医薬品、化粧料等の製品に配合可能であることを限度として特に制限されない。例えば、トコフェロール及びトコトリエノールは、α−、β−、γ−、及びδ−のいずれであってもよく、またｄ体又はｄｌ体のいずれであってもよい。また、例えば、ビタミンＥの誘導体としては、酢酸トコフェロール、コハク酸トコフェロール、リノール酸トコフェロール、リノレイン酸トコフェロール、ニコチン酸トコフェロール、（リノール酸／オレイン酸）トコフェロール等のトコフェロール有機酸エステル等が挙げられる。 Vitamin E refers to vitamin E (tocopherol, tocotrienol) and its derivatives. The types of vitamin E used in the present invention are not particularly limited as long as they can be blended in products such as foods and drinks, oral care products, pharmaceuticals, and cosmetics. For example, tocopherols and tocotrienols may be any of α-, β-, γ-, and δ-, and may be either d-form or dl-form. In addition, for example, as a derivative of vitamin E, tocopherol organic acid esters such as tocopherol acetate, tocopherol succinate, tocopherol linoleate, tocopherol linoleate, tocopherol nicotinate, and tocopherol (linoleic acid / oleic acid) can be mentioned.
これらのビタミンＥ類は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These vitamin Es may be used alone or in combination of two or more.
これらのビタミンＥ類の中でも、より一層効果的にビタミンＢ12類の光安定化を図るという観点から、好ましくはトコフェロールの誘導体、より好ましくはトコフェロール酢酸エステルが挙げられる。 Among these vitamin E, from the viewpoint of more effectively achieving the photostability of the vitamin B 12 compound, preferably derivatives of tocopherol, or more preferably tocopherol acetate.
本発明のビタミンＢ12類含有組成物にビタミンＥ類を含有させる場合、ビタミンＢ12類とビタミンＥ類との比率としては、例えば、ビタミンＢ12類１重量部当たり、ビタミンＥ類が０．００１２５〜１０００重量部、好ましくは０．０２５〜２５０重量部、より好ましくは２．５〜２５０重量部が挙げられる。 When the vitamin B 12- containing composition of the present invention contains vitamin E, the ratio of vitamin B 12 to vitamin E is, for example, 0. Vitamin E per 1 part by weight of vitamin B 12 . 00125 to 1000 parts by weight, preferably 0.025 to 250 parts by weight, and more preferably 2.5 to 250 parts by weight.
また、本発明のビタミンＢ12類含有組成物にビタミンＥ類を含有させる場合、ビタミンＢ12類含有組成物におけるビタミンＥ類の濃度としては、例えば、０．０００２５〜０．１重量％、好ましくは０．０００５〜０．０５重量％、より好ましくは０．０００５〜０．００５重量％が挙げられる。 When the vitamin B 12- containing composition of the present invention contains vitamin E, the concentration of vitamin E in the vitamin B 12- containing composition is, for example, 0.00025 to 0.1% by weight, preferably 0.00025 to 0.1% by weight. Is 0.0005 to 0.05% by weight, more preferably 0.0005 to 0.005% by weight.
［キレート剤］
本発明のビタミンＢ12類含有組成物は、更にキレート剤を含有してもよい。本発明で使用されるキレート剤の種類については、飲食品、口腔ケア製品、医薬品、化粧料等の製品に配合可能であることを限度として特に制限されないが、例えば、エデト酸、クエン酸、コハク酸、及びこれら塩等が挙げられる。塩の形態としては、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩等が挙げられる。これらのキレート剤は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。
[Chelating agent]
The vitamin B 12- containing composition of the present invention may further contain a chelating agent. The type of chelating agent used in the present invention is not particularly limited as long as it can be blended in products such as foods and drinks, oral care products, pharmaceuticals, cosmetics, etc., but for example, edetic acid, citric acid, and succinic acid. Acids, salts thereof and the like can be mentioned. Examples of the salt form include alkali metal salts such as sodium salt and potassium salt. These chelating agents may be used alone or in combination of two or more.
これらのキレート剤の中でも、好ましくはエデト酸及びその塩、より好ましくはエデト酸ナトリウムが挙げられる。 Among these chelating agents, edetic acid and a salt thereof are preferable, and sodium edetate is more preferable.
また、本発明のビタミンＢ12類含有組成物においてキレート剤を含有させる場合、ビタミンＢ12類含有組成物におけるキレート剤の濃度については、特に制限されないが、例えば、０．００１〜０．３重量％、好ましくは０．００５〜０．１重量％、より好ましくは０．０１〜０．１重量％が挙げられる。 When the chelating agent is contained in the vitamin B 12- containing composition of the present invention, the concentration of the chelating agent in the vitamin B 12- containing composition is not particularly limited, but is, for example, 0.001 to 0.3 weight. %, preferably 0.005 to 0.1% by weight, more preferably 0.01 to 0.1% by weight.
［多価アルコール］
本発明のビタミンＢ12類含有組成物は、更に多価アルコールを含有してもよい。本発明で使用される多価アルコールの種類としては、例えば、エチレングリコール、１，３−ブチレングリコール、プロピレングリコール、イソプレングリコール、ジエチレングリコール、ジプロピレングリコール、ポリプロピレングリコール、グリセリン等が挙げられる。これらの多価アルコールは、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。
[Multivalent alcohol]
The vitamin B 12- containing composition of the present invention may further contain a polyhydric alcohol. Examples of the type of polyhydric alcohol used in the present invention include ethylene glycol, 1,3-butylene glycol, propylene glycol, isoprene glycol, diethylene glycol, dipropylene glycol, polypropylene glycol, glycerin and the like. These polyhydric alcohols may be used alone or in combination of two or more.
これらの多価アルコールの中でも、好ましくプロピレングリコールが挙げられる。 Among these polyhydric alcohols, propylene glycol is preferably mentioned.
また、本発明のビタミンＢ12類含有組成物に多価アルコールを含有させる場合、ビタミンＢ12類含有組成物における多価アルコールの濃度については、特に制限されないが、例えば、０．０１〜１０重量％、好ましくは０．１〜５重量％、より好ましくは０．１〜１重量％が挙げられる。 When the vitamin B 12- containing composition of the present invention contains a polyhydric alcohol, the concentration of the polyhydric alcohol in the vitamin B 12- containing composition is not particularly limited, but is, for example, 0.01 to 10 weight. %, preferably 0.1 to 5% by weight, more preferably 0.1 to 1% by weight.
［その他の成分］
本発明のビタミンＢ12類含有組成物には、前記成分の他に、当該ビタミンＢ12類含有組成物の形状や製品形態に応じて、各種の薬理成分、食品素材、添加剤等の成分を含有させてもよい。このような成分は、ビタミンＢ12類含有組成物の形状や製品形態に応じて使用可能なものを適宜選定すればよいが、例えば、水、薬理成分、清涼化剤、界面活性剤（ポリオキシエチレンソルビタン脂肪酸エステル以外）、油脂類、ロウ類、炭化水素類、脂肪酸類、高級アルコール類、エステル類、水溶性高分子、金属石鹸、１価低級アルコール類、ｐＨ調整剤、緩衝剤、酸化防止剤、紫外線防止剤、防腐剤、香料、粉体、増粘剤、色素等が挙げられる。これらの成分は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。これらの成分の濃度については、使用する成分の種類や組成物の形状及び製品形態等に応じて適宜設定される。
[Other ingredients]
In addition to the above-mentioned components, the vitamin B 12- containing composition of the present invention contains various pharmacological components, food materials, additives and other components according to the shape and product form of the vitamin B 12- containing composition. It may be contained. Such components may be suitably selected usable in accordance with the shape and product forms of vitamin B 12 analog-containing composition, for example, water, the pharmaceutical agent, cooling agent, surfactant (polyoxy (Other than ethylene sorbitan fatty acid esters), fats and oils, waxes, hydrocarbons, fatty acids, higher alcohols, esters, water-soluble polymers, metal soaps, monohydric lower alcohols, pH adjusters, buffers, antioxidants Examples include agents, UV inhibitors, preservatives, fragrances, powders, thickeners, pigments and the like. These components may be used alone or in combination of two or more. The concentration of these components is appropriately set according to the type of component used, the shape of the composition, the product form, and the like.
［ビタミンＢ12類含有組成物の形状・製品形態等］
本発明のビタミンＢ12類含有組成物は、水性組成物又は非水性組成物のいずれであってもよい。一般的にビタミンＢ12類は水性組成物中で光暴露により分解され易くなる傾向があるが、本発明によれば、水性組成物中でも光暴露によるビタミンＢ12類の分解を効果的に抑制できる。このような本発明の効果を鑑みると、本発明のビタミンＢ12類含有組成物の好適な例として水性組成物が挙げられる。
Shape-product forms such as vitamin B 12 analog-containing composition]
The vitamin B 12- containing composition of the present invention may be either an aqueous composition or a non-aqueous composition. In general, vitamin B 12s tend to be easily decomposed by light exposure in an aqueous composition, but according to the present invention, the decomposition of vitamin B 12s by light exposure can be effectively suppressed even in an aqueous composition. .. In view of such effects of the present invention, an aqueous composition can be mentioned as a suitable example of the vitamin B 12- containing composition of the present invention.
水性組成物とは、水を含有する組成物である。水性組成物における水の濃度としては、具体的には、５０量％以上、好ましくは５０〜９９．９９重量％、より好ましくは５０〜９９．８重量％が挙げられる。水性組成物の形状としては、例えば、液状、ゲル状、ペースト状等が挙げられる。 The aqueous composition is a composition containing water. Specific examples of the concentration of water in the aqueous composition include 50% by weight or more, preferably 50 to 99.99% by weight, and more preferably 50 to 99.8% by weight. Examples of the shape of the aqueous composition include liquid, gel, and paste.
ビタミンＢ12類含有組成物が水性組成物である場合、そのｐＨとしては、例えば、４．０〜８．０、好ましくは５．０〜７．７、より好ましくは５．５〜７．０が挙げられる。 When the vitamin B 12- containing composition is an aqueous composition, the pH thereof is, for example, 4.0 to 8.0, preferably 5.0 to 7.7, and more preferably 5.5 to 7.0. Can be mentioned.
また、非水性組成物とは、配合成分の吸湿によって不可避的に含まれる水を除いて、水が実質的に配合されていない組成物である。非水性組成物の形状としては、例えば、粉末状、顆粒状、錠剤状、丸剤状、軟膏状等が挙げられる。 Further, the non-aqueous composition is a composition in which water is substantially not blended, except for water which is inevitably contained due to moisture absorption of the blending component. Examples of the shape of the non-aqueous composition include powder, granule, tablet, pill, ointment and the like.
本発明のビタミンＢ12類含有組成物の製品形態については、特に制限されず、例えば、飲食品、口腔ケア製品、医薬品、化粧料等が挙げられる。 The product form of the composition containing vitamin B 12 of the present invention is not particularly limited, and examples thereof include foods and drinks, oral care products, pharmaceuticals, and cosmetics.
飲食品としては、例えば、清涼飲料水、酒類、栄養ドリンク、コーヒー、茶、牛乳、果汁飲料、清涼飲料等の飲料；錠剤、顆粒剤、粉剤、ゼリー剤、散剤、懸濁剤、シロップ剤、カプセル剤（ソフトカプセル剤、ハードカプセル剤）等のサプリメント；チーズ、ウインナー、ソーセージ、ハム、魚介加工品等の副菜；アイスクリーム、クッキー、ケーキ、ゼリー、プリン、キャンディー、チューインガム、ヨーグルト、グミ、チョコレート、ビスケット等の菓子類等が挙げられる。 Foods and drinks include, for example, soft drinks, alcoholic beverages, nutritional drinks, coffee, tea, milk, fruit juice drinks, soft drinks and other beverages; tablets, granules, powders, jellies, powders, suspending agents, syrups, etc. Supplements such as capsules (soft capsules, hard capsules); side dishes such as cheese, wieners, sausages, hams, processed seafood; ice cream, cookies, cakes, jellies, puddings, candies, chewing gum, yogurt, gummies, chocolate, Examples include confectionery such as biscuits.
口腔ケア製品としては、例えば、練歯磨剤、粉歯磨剤、液体歯磨剤等の歯磨剤；歯用クリーム；マウスウォッシュ、含嗽剤等の洗口剤；口腔用パスタ剤、マウススプレー、口腔内崩壊性フィルム、ゲル、トローチ、タブレット、チュアブル、口腔用軟膏剤等が挙げられる。 Oral care products include, for example, dentifrices such as dentifrices, powdered dentifrices, and liquid dentifrices; tooth creams; mouthwashes such as mouthwashes and mouthwashes; oral pasta agents, mouth sprays, and oral disintegration. Examples include sex films, gels, troches, tablets, chewables, oral ointments and the like.
医薬品としては、例えば、散剤、顆粒剤、錠剤、カプセル剤、丸剤、液剤等の内服用の医薬品；輸液、注射剤等の皮下、血管内又は腹腔内投与用の医薬品；液剤（ローション剤、スプレー剤、エアゾール剤、及び乳液剤を含む）、水溶性軟膏剤、油脂性軟膏剤、クリーム剤、フォーム剤、ジェル剤、貼付剤、点眼剤、洗眼剤等の皮膚又は粘膜用の医薬品等が挙げられる。 Examples of pharmaceuticals include powders, granules, tablets, capsules, pills, liquids and the like for internal use; subcutaneous, intravascular or intraperitoneal administration of infusions, injections and the like; liquids (lotions, lotions, etc.) (Including sprays, aerosols, and emulsions), water-soluble ointments, oily ointments, creams, foams, gels, patches, eye drops, eye wash, and other skin or mucous medicines. Can be mentioned.
化粧料としては、例えば、軟膏、クリーム、乳液、化粧水、ローション、パック、ゲル等の基礎化粧料；ファンデーション、アイシャドウ、口紅、頬紅等のメークアップ化粧料等が挙げられる。 Examples of cosmetics include basic cosmetics such as ointments, creams, milky lotions, lotions, lotions, facial masks, and gels; make-up cosmetics such as foundations, eye shadows, lipsticks, and blushers.
以下に実施例を示して本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。 The present invention will be described in more detail with reference to Examples below, but the present invention is not limited thereto.
試験例１
表１に示す組成の水性組成物を調製した。５００ｍｌ容の透明容器（ポリエチレンテレフタレート製）に得られた水性組成物５００ｍｌを充填し、昼間に直射日光が当たる室内（南側の窓から１０ｃｍ離れた場所）に３５日間静置した。３５日間の静置後に、水性組成物の外観を目視にて観察し、以下の判定基準に従って、シアノコバラミンの保存安定性を判定した。なお、シアノコバラミンはピンク色の色調を呈し、分解されると退色するため、本試験において、退色が多い程、シアノコバラミンの分解が進んでいることを示している。
＜シアノコバラミンの保存安定性＞
◎ ：製造直後に比べて、色調が同等である。
○ ：製造直後に比べて、僅かに退色が認められるが許容範囲内である。
× ：製造直後に比べて、明らかに退色が認められ許容できない。
××：退色が著しく、ほぼ無色になっている。
Test Example 1
An aqueous composition having the composition shown in Table 1 was prepared. A 500 ml transparent container (made of polyethylene terephthalate) was filled with 500 ml of the obtained aqueous composition, and allowed to stand in a room exposed to direct sunlight in the daytime (a place 10 cm away from the window on the south side) for 35 days. After standing for 35 days, the appearance of the aqueous composition was visually observed, and the storage stability of cyanocobalamin was determined according to the following criteria. It should be noted that cyanocobalamin exhibits a pink color tone and fades when decomposed. Therefore, in this test, it is shown that the more fading, the more the decomposition of cyanocobalamin progresses.
<Cyanocobalamin storage stability>
⊚: The color tone is the same as that immediately after manufacturing.
◯: Slight fading is observed as compared with immediately after production, but it is within the permissible range.
X: Color fading is clearly observed and unacceptable as compared with immediately after production.
XX: Fading is remarkable and it is almost colorless.
結果を表１に示す。この結果、水性組成物中で、シアノコバラミン及びポリソルベート８０を共存させても、シアノコバラミン１重量部当たりポリソルベート８０が１０重量部超である場合には、光暴露によるシアノコバラミンの分解を抑制できていなかった。これに対して、水性組成物中でシアノコバラミンと共にポリソルベート８０を共存させ、且つシアノコバラミン１重量部当たりポリソルベート８０が１０重量部以下の場合には、光暴露によるシアノコバラミンの分解を抑制できることが確認された。また、水性組成物中でシアノコバラミンと、シアノコバラミン１重量部当たり１０重量部以下のポリソルベート８０と共に、トコフェロール酢酸エステルを含有させた場合には、光暴露によるシアノコバラミンの分解を格段効果的に抑制できることも明らかとなった。 The results are shown in Table 1. As a result, even if cyanocobalamin and polysorbate 80 coexisted in the aqueous composition, when the polysorbate 80 per 1 part by weight of cyanocobalamin was more than 10 parts by weight, the decomposition of cyanocobalamin by light exposure could not be suppressed. On the other hand, it was confirmed that when polysorbate 80 coexists with cyanocobalamin in the aqueous composition and the polysorbate 80 per 1 part by weight of cyanocobalamin is 10 parts by weight or less, the decomposition of cyanocobalamin by light exposure can be suppressed. It is also clear that when cyanocobalamin and tocopherol acetic acid ester are contained together with polysorbate 80 of 10 parts by weight or less per 1 part by weight of cyanocobalamin in the aqueous composition, the decomposition of cyanocobalamin by light exposure can be suppressed remarkably effectively. It became.
処方例
表２に示す組成の水性組成物を調製した。得られた水性組成物を、前記試験例１と同様の方法でシアノコバラミンの保存安定性を評価したところ、いずれも、光暴露によるシアノコバラミンの分解を効果的に抑制できていた。
Formulation Examples An aqueous composition having the composition shown in Table 2 was prepared. When the storage stability of cyanocobalamin was evaluated for the obtained aqueous composition by the same method as in Test Example 1, the decomposition of cyanocobalamin due to light exposure could be effectively suppressed in each case.
Claims (4)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019102033A JP2020196672A (en) | 2019-05-31 | 2019-05-31 | Vitamin B12-containing composition |
| CN202080034923.2A CN113811314A (en) | 2019-05-31 | 2020-05-19 | Composition containing vitamin B12 |
| PCT/JP2020/019747 WO2020241374A1 (en) | 2019-05-31 | 2020-05-19 | Vitamin b12 compound-containing composition |
| JP2023207968A JP2024023610A (en) | 2019-05-31 | 2023-12-08 | Vitamin b12-containing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019102033A JP2020196672A (en) | 2019-05-31 | 2019-05-31 | Vitamin B12-containing composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023207968A Division JP2024023610A (en) | 2019-05-31 | 2023-12-08 | Vitamin b12-containing composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2020196672A true JP2020196672A (en) | 2020-12-10 |
Family
ID=73552975
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019102033A Pending JP2020196672A (en) | 2019-05-31 | 2019-05-31 | Vitamin B12-containing composition |
| JP2023207968A Pending JP2024023610A (en) | 2019-05-31 | 2023-12-08 | Vitamin b12-containing composition |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023207968A Pending JP2024023610A (en) | 2019-05-31 | 2023-12-08 | Vitamin b12-containing composition |
Country Status (3)
| Country | Link |
|---|---|
| JP (2) | JP2020196672A (en) |
| CN (1) | CN113811314A (en) |
| WO (1) | WO2020241374A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020196669A (en) * | 2019-05-31 | 2020-12-10 | 小林製薬株式会社 | Vitamin b12 photostabilizing method |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005154437A (en) * | 2003-11-07 | 2005-06-16 | Rohto Pharmaceut Co Ltd | Pharmaceutical composition comprising tranilast |
| JP2005247799A (en) * | 2004-03-08 | 2005-09-15 | Zeria Pharmaceut Co Ltd | Eye drop |
| JP2008100957A (en) * | 2006-10-20 | 2008-05-01 | Taisho Pharmaceutical Co Ltd | Eye drop |
| JP2010521507A (en) * | 2007-03-16 | 2010-06-24 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Stabilization of vitamin B12 |
| JP2012031184A (en) * | 2011-09-16 | 2012-02-16 | Kobayashi Pharmaceutical Co Ltd | Ophthalmic composition |
| WO2018066651A1 (en) * | 2016-10-07 | 2018-04-12 | ライオン株式会社 | Ophthalmic product and method for inhibiting viscosity decrease |
| JP2019065003A (en) * | 2017-09-29 | 2019-04-25 | 参天製薬株式会社 | Aqueous composition containing stabilized cyanocobalamin and method for stabilizing cyanocobalamin |
| JP2019147755A (en) * | 2018-02-27 | 2019-09-05 | ロート製薬株式会社 | Ophthalmic composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101711769A (en) * | 2009-11-23 | 2010-05-26 | 北京京卫信康医药科技发展有限公司 | Stable injection composite of 12 complex vitamins and preparation method thereof |
-
2019
- 2019-05-31 JP JP2019102033A patent/JP2020196672A/en active Pending
-
2020
- 2020-05-19 WO PCT/JP2020/019747 patent/WO2020241374A1/en active Application Filing
- 2020-05-19 CN CN202080034923.2A patent/CN113811314A/en active Pending
-
2023
- 2023-12-08 JP JP2023207968A patent/JP2024023610A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005154437A (en) * | 2003-11-07 | 2005-06-16 | Rohto Pharmaceut Co Ltd | Pharmaceutical composition comprising tranilast |
| JP2005247799A (en) * | 2004-03-08 | 2005-09-15 | Zeria Pharmaceut Co Ltd | Eye drop |
| JP2008100957A (en) * | 2006-10-20 | 2008-05-01 | Taisho Pharmaceutical Co Ltd | Eye drop |
| JP2010521507A (en) * | 2007-03-16 | 2010-06-24 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Stabilization of vitamin B12 |
| JP2012031184A (en) * | 2011-09-16 | 2012-02-16 | Kobayashi Pharmaceutical Co Ltd | Ophthalmic composition |
| WO2018066651A1 (en) * | 2016-10-07 | 2018-04-12 | ライオン株式会社 | Ophthalmic product and method for inhibiting viscosity decrease |
| JP2019065003A (en) * | 2017-09-29 | 2019-04-25 | 参天製薬株式会社 | Aqueous composition containing stabilized cyanocobalamin and method for stabilizing cyanocobalamin |
| JP2019147755A (en) * | 2018-02-27 | 2019-09-05 | ロート製薬株式会社 | Ophthalmic composition |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020196669A (en) * | 2019-05-31 | 2020-12-10 | 小林製薬株式会社 | Vitamin b12 photostabilizing method |
| JP7436151B2 (en) | 2019-05-31 | 2024-02-21 | 小林製薬株式会社 | Method for photostabilizing vitamin B12s |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113811314A (en) | 2021-12-17 |
| JP2024023610A (en) | 2024-02-21 |
| WO2020241374A1 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003062182A1 (en) | Method for stabilizing reduced coenzyme q10 and composition therefor | |
| JP6523971B2 (en) | Composition containing reduced coenzyme Q10 | |
| JP2024023610A (en) | Vitamin b12-containing composition | |
| WO2018202832A1 (en) | Organic hydroperoxide reduction in perfumery raw materials and food raw materials | |
| KR20150081249A (en) | Oral composition | |
| JP7270465B2 (en) | Method for photostabilizing vitamin B12s | |
| JP7436151B2 (en) | Method for photostabilizing vitamin B12s | |
| EP3305757B1 (en) | 10-hydroxy-cis-12-octadecenoic acid alkyl ester and use thereof | |
| KR20060123736A (en) | Novel liquid preparation composition | |
| JP2018161150A (en) | Liquid food composition | |
| JP2006257010A (en) | WATER-SOLUBLE COMPOSITION OF alpha-LIPOIC ACID, BEVERAGE OR FOOD AND COSMETIC EACH CONTAINING THE SAME COMPOSITION AND METHOD FOR PRODUCING THE SAME COMPOSITION | |
| JP7368108B2 (en) | aqueous composition | |
| JP2010090080A (en) | Vinegar-containing soft capsule prevented from or suppressed in delayed disintegration | |
| JP6762782B2 (en) | An acidic composition with excellent stability of the folic acid contained | |
| JP4965530B2 (en) | Benzene production inhibitor and method for inhibiting benzene production | |
| KR20090030281A (en) | Tooth enamel dissolution inhibitor | |
| US20210353557A1 (en) | Oral composition containing reduced coenzyme q10, method for producing same, method for preventing discoloration and discoloration preventing agent | |
| JP2018000080A (en) | Folic acid-containing acidic composition having excellent stability of folic acid | |
| JP7201142B2 (en) | Folic acid-containing acidic composition with excellent stability of folic acid | |
| JP3618336B2 (en) | Coenzyme Q10-containing composition | |
| EP3618799A1 (en) | Organic hydroperoxide reduction in perfumery raw materials and food raw materials | |
| JP4689114B2 (en) | Capsules containing vitamins and processed vats | |
| JPH0630746A (en) | Sterilization of food containing ascorbic acid | |
| JP6602578B2 (en) | Oral composition | |
| JP2015086171A (en) | Coated powder comprising pyrroloquinoline quinones, and production method thereof, as well as composition thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220414 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230418 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230612 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231208 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231215 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20240216 |